Charles River Laboratories International (CRL)
(Delayed Data from NYSE)
$218.83 USD
+4.86 (2.27%)
Updated Jul 1, 2022 04:00 PM ET
3-Hold of 5 3
B Value A Growth D Momentum B VGM
Fundamental Charts
About PE Ratio (TTM)
Charles River Laboratories International, Inc. has a trailing-twelve-months P/E of 20.28X compared to the Medical Services industry's P/E of 21.29X.
Price to Earnings Ratio or P/E is price / earnings. It is the most commonly used metric for determining a company's value relative to its earnings. In this example, we are using the actual earnings (EPS) for the trailing twelve months (or TTM). A stock with a P/E ratio of 20, for example, is said to be trading at 20 times its trailing twelve months earnings. In general, a lower number or multiple is usually considered better than a higher one.
CRL 218.83 +4.86(2.27%)
Will CRL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CRL based on the 1-3 month trading system that nearly triples the S&P 500.
Zacks News for CRL
Charles River (CRL) Signs saRNA-Based Vaccine Manufacture Deal
Charles River (CRL) Prospers Internationally Amid FX Headwind
CRL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Charles River (CRL) to Create New Gene Therapy for Hemophilia A
Why Is Charles River (CRL) Down 1.2% Since Last Earnings Report?
Why Charles River Laboratories (CRL) is a Top Value Stock for the Long-Term
Other News for CRL
Charles River Laboratories Announces Opening of U.K. Manufacturing Facility
Charles River Laboratories opens manufacturing facility in Cheshire, UK
Charles River opens Plasmid DNA Centre in Cheshire
Enzo Biochem: Activist Pressure Could Finally Lead To A Company Sale
Charles River Laboratories International Now #440 Largest Company, Surpassing Host Hotels & Resorts